Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lanreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 known ✓ | P35346 | 16/20 | 1.00 |
| ▸ | SSTR2 known ✓ | P30874 | 16/20 | 1.00 |
| ▸ | SSTR3 | P32745 | 9/20 | 1.00 |
| ▸ | SSTR1 | P30872 | 3/20 | 1.00 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanreotide SCHEMBL29402091 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL19472556 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29381700 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29356077 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL14802383 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL19962799 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL14674691 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29450601 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL21091289 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL28187023 | 0.99 | SSTR5 (0.99) | SSTR5SSTR2SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
| US-20210024579-A1 | MACROCYCLIZATION OF PEPTIDOMIMETICS | UNIVERSITY OF WARWICK (GB) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024579-A1 | MACROCYCLIZATION OF PEPTIDOMIMETICS | NGLY1, MAX, VIP | SSTR5 210/4885SSTR2 284/4885SSTR3 92/4885 |
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | SSTR5 465/4885SSTR2 314/4885SSTR3 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.